Moderna Inc (MRNA)

$49.20 -0.83 (-1.66%)
Market Cap 19.43B
Revenue (ttm) 1.94B
Net Income (ttm) -2.82B
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -145.16%
Debt to Equity Ratio 0.07
Volume 4,631,700
Avg Vol 10,241,238
Day's Range N/A - N/A
Shares Out 394.94M
Stochastic %K 27%
Beta 1.33
Analysts Hold
Price Target $43.80

Company Profile

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseas...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 714 6500
Address:
325 Binney Street, Cambridge, United States
Auto_MA_T_Ka
Auto_MA_T_Ka Apr. 5 at 6:19 PM
Moderna $MRNA is still at its weekly MA support, sitting nicely. -- 📉BEST Respected MA S&R Lines📈
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Apr. 4 at 7:10 PM
$MRNA $RLAY $RXRX $ABSI $SPY
1 · Reply
UsingAGodAlgorithm
UsingAGodAlgorithm Apr. 4 at 3:40 AM
$RH -81% from short entry. We called the top perfectly on this name. One of many calls we were the only ones on all ST to make. Check our profile. $DLTR $SOFI $MRNA $ULTA
0 · Reply
DragonAlgo
DragonAlgo Apr. 3 at 11:44 PM
🐉 $MRNA CALL — DragonAlgo® Signal Contract: MRNA CALL Expiry: 2026-04-10 | Strike: $49.00 | Type: CALL Option Plan (premium): Entry: $2.06 Stop: $1.48 TP1: $2.68 TP2: $3.50 TP3: $4.94 🔗 https://dragonalgo.com
0 · Reply
Davidendz
Davidendz Apr. 3 at 1:37 PM
Biotech gets called “scam” on volatility, but that’s noise. What matters is data and execution. Across names like $BVAXF $BIOV.CSE,$MRNA, $BNTX, and $NVAX, it’s the same cycle: filings, catalysts, then price moves. Clinical progress > headlines.
0 · Reply
DragonAlgo
DragonAlgo Apr. 3 at 8:38 AM
🐉 $MRNA CALL — DragonAlgo® Signal Contract: MRNA CALL Expiry: 2026-04-10 | Strike: $49.00 | Type: CALL Option Plan (premium): Entry: $2.06 Stop: $1.48 TP1: $2.68 TP2: $3.50 TP3: $4.94 🔗 https://dragonalgo.com
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Apr. 2 at 9:26 PM
$MRNA RSI: 39.38, MACD: 0.1618 Vol: 2.11, MA20: 52.31, MA50: 49.09 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
SparkyReturns
SparkyReturns Apr. 2 at 7:15 PM
$ICU I can almost feel the rumble of my new cigarette boat.... And to think my money is helping to bring a life-saving device to market for those most in need in the ICU. Wow. $XERS $ESPR $MRNA $PFE ra
1 · Reply
DragonAlgo
DragonAlgo Apr. 2 at 6:12 PM
🐉 $MRNA PUT — DragonAlgo® Signal Contract: MRNA PUT Expiry: 2026-04-10 | Strike: $47.00 | Type: PUT Option Plan (premium): Entry: $1.16 Stop: $0.83 TP1: $1.50 TP2: $1.96 TP3: $2.77 Active momentum environment. 🔗 https://dragonalgo.com
0 · Reply
G101SPM
G101SPM Apr. 2 at 5:37 PM
#OPTIONACTION $SNAP Apr 5 calls are seeing interest with the underlying stock down 6% (volume: 7.0K, open int: 46.3K, implied vol: ~84%, prev day implied vol: 71%). 2500 contracts traded a single transaction. We noted call activity in the same strike yesterday (see 4/1 13:29 OPTNX). Co is expected to report earnings mid-April. $MSTR Weekly Apr02 137 calls (volume: 15.2K, open int: 16.5K, implied vol: ~75%, prev day implied vol: 69%). Co is expected to report earnings early May. $MRNA Weekly Apr02 53 calls (volume: 16.0K, open int: 16.2K, implied vol: ~76%, prev day implied vol: 72%). 5.9K traded in a single transaction. Co is expected to report earnings in late April. $PYPL Weekly Apr10 45 calls (volume: 5.2K, open int: 650, implied vol: ~45%, prev day implied vol: 42%). 3.9K traded in a single transaction. Co is confirmed to report earnings on May 5 before the open. $AAL Weekly Apr10 10 puts (volume: 5.4K, open int: 5.6K, implied vol: ~62%, prev day implied vol: 57%). Airline shares are falling amid a rise in oil prices. Co is expected to report earnings in late April.
0 · Reply
Latest News on MRNA
Moderna, Inc. (MRNA) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Mar 10, 2026, 11:40 AM EDT - 26 days ago

Moderna, Inc. (MRNA) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

What's Going On With Moderna, Capricor, Other Biotech Stocks On Monday?

Mar 9, 2026, 1:32 PM EDT - 27 days ago

What's Going On With Moderna, Capricor, Other Biotech Stocks On Monday?

CAPR

FDA reversals leave investors worrying about the fates of other experimental drugs

Mar 6, 2026, 11:33 AM EST - 4 weeks ago

FDA reversals leave investors worrying about the fates of other experimental drugs

DNLI RGNX WVE

The Sun Will Shine On Moderna Again - Initiating With A Buy

Mar 4, 2026, 3:16 PM EST - 4 weeks ago

The Sun Will Shine On Moderna Again - Initiating With A Buy

Why Moderna's $950M Patent Bill Is A Small Price For Pipeline Freedom

Mar 4, 2026, 11:05 AM EST - 4 weeks ago

Why Moderna's $950M Patent Bill Is A Small Price For Pipeline Freedom

Moderna rises as up to $2.25 billion settlement for COVID vaccine patent dispute to remove overhang

Mar 4, 2026, 8:26 AM EST - 4 weeks ago

Moderna rises as up to $2.25 billion settlement for COVID vaccine patent dispute to remove overhang

Moderna's $950 Million Settlement Clears Legal Overhang, Stock Soars

Mar 4, 2026, 8:14 AM EST - 4 weeks ago

Moderna's $950 Million Settlement Clears Legal Overhang, Stock Soars

Moderna Stock Rallies. This Big Risk Just Got Eliminated.

Mar 4, 2026, 5:25 AM EST - 4 weeks ago

Moderna Stock Rallies. This Big Risk Just Got Eliminated.

Moderna's stock rallies more than 10% as deal over a patent dispute clears vaccine pipeline

Mar 3, 2026, 5:30 PM EST - 4 weeks ago

Moderna's stock rallies more than 10% as deal over a patent dispute clears vaccine pipeline

Moderna to Pay $950 Million to Settle Patent Cases From Arbutus, Genevant

Mar 3, 2026, 4:46 PM EST - 4 weeks ago

Moderna to Pay $950 Million to Settle Patent Cases From Arbutus, Genevant

ABUS

Moderna agrees to pay up to $2.25 billion to settle COVID vaccine patent dispute

Mar 3, 2026, 4:26 PM EST - 4 weeks ago

Moderna agrees to pay up to $2.25 billion to settle COVID vaccine patent dispute

ABUS ROIV

Moderna, Inc. (MRNA) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Mar 3, 2026, 4:22 PM EST - 4 weeks ago

Moderna, Inc. (MRNA) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Roivant Announces Genevant Sciences' and Arbutus Biopharma's $2.25 Billion Global Settlement With Moderna

Mar 3, 2026, 4:15 PM EST - 4 weeks ago

Roivant Announces Genevant Sciences' and Arbutus Biopharma's $2.25 Billion Global Settlement With Moderna

ABUS ROIV

Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna

Mar 3, 2026, 4:15 PM EST - 4 weeks ago

Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna

ABUS ROIV

Moderna Resolves Global Patent Litigation with Arbutus/Genevant

Mar 3, 2026, 4:15 PM EST - 4 weeks ago

Moderna Resolves Global Patent Litigation with Arbutus/Genevant

ABUS

Moderna's Covid-Flu Vaccine Recommended for Approval in EU

Feb 27, 2026, 7:23 AM EST - 5 weeks ago

Moderna's Covid-Flu Vaccine Recommended for Approval in EU

European Medicines Agency's Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Marketing Authorization of mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19

Feb 27, 2026, 7:00 AM EST - 5 weeks ago

European Medicines Agency's Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Marketing Authorization of mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19

Moderna gets EU regulator nod for combined COVID, flu vaccine

Feb 27, 2026, 6:09 AM EST - 5 weeks ago

Moderna gets EU regulator nod for combined COVID, flu vaccine

Moderna Stock: How Far Can The Flu Shot Fly?

Feb 24, 2026, 10:40 AM EST - 5 weeks ago

Moderna Stock: How Far Can The Flu Shot Fly?

US FDA Commissioner Makary says FDA supports mRNA vaccines but US taxpayers should not bear the cost

Feb 23, 2026, 3:15 PM EST - 5 weeks ago

US FDA Commissioner Makary says FDA supports mRNA vaccines but US taxpayers should not bear the cost

MRK PFE

BioNTech sues Moderna for patent infringement over COVID-19 shots

Feb 19, 2026, 1:25 PM EST - 6 weeks ago

BioNTech sues Moderna for patent infringement over COVID-19 shots

BNTX

Moderna to Present at Upcoming Conferences in March 2026

Feb 19, 2026, 7:00 AM EST - 6 weeks ago

Moderna to Present at Upcoming Conferences in March 2026

FDA Makes U-Turn Again On Moderna New Flu Vaccine Review, Stock Soars

Feb 18, 2026, 1:20 PM EST - 6 weeks ago

FDA Makes U-Turn Again On Moderna New Flu Vaccine Review, Stock Soars

FDA agrees to review Moderna's mRNA flu vaccine application in a reversal

Feb 18, 2026, 11:17 AM EST - 6 weeks ago

FDA agrees to review Moderna's mRNA flu vaccine application in a reversal

Moderna Shares Rally 6% After FDA Reverses Decision Not To Review Flu Vaccine

Feb 18, 2026, 11:00 AM EST - 6 weeks ago

Moderna Shares Rally 6% After FDA Reverses Decision Not To Review Flu Vaccine

Moderna got the FDA to change its mind and review its flu vaccine after some concessions

Feb 18, 2026, 10:22 AM EST - 6 weeks ago

Moderna got the FDA to change its mind and review its flu vaccine after some concessions

FDA reverses decision not to review Moderna's new flu vaccine

Feb 18, 2026, 9:35 AM EST - 6 weeks ago

FDA reverses decision not to review Moderna's new flu vaccine

Moderna Says FDA Will Review Its Flu Vaccine. The Stock Is Rising.

Feb 18, 2026, 9:27 AM EST - 6 weeks ago

Moderna Says FDA Will Review Its Flu Vaccine. The Stock Is Rising.

The FDA reversed course and agreed to begin a review of Moderna's seasonal flu shot

Feb 18, 2026, 9:12 AM EST - 6 weeks ago

The FDA reversed course and agreed to begin a review of Moderna's seasonal flu shot

Health Rounds: Moderna combo flu/COVID vaccine succeeds in mid-stage trial

Feb 18, 2026, 7:13 AM EST - 6 weeks ago

Health Rounds: Moderna combo flu/COVID vaccine succeeds in mid-stage trial

US FDA to initiate review of Moderna's influenza vaccine

Feb 18, 2026, 7:07 AM EST - 6 weeks ago

US FDA to initiate review of Moderna's influenza vaccine

Moderna Announces the U.S. Food and Drug Administration will Initiate the Review of Its Investigational Seasonal Influenza Vaccine Submission

Feb 18, 2026, 7:00 AM EST - 6 weeks ago

Moderna Announces the U.S. Food and Drug Administration will Initiate the Review of Its Investigational Seasonal Influenza Vaccine Submission

Moderna Receives European Commission Marketing Authorization for COVID-19 Vaccine mNEXSPIKE

Feb 17, 2026, 7:00 AM EST - 6 weeks ago

Moderna Receives European Commission Marketing Authorization for COVID-19 Vaccine mNEXSPIKE

Moderna, Inc. (MRNA) Price Forecast: Breakout Signals New Bull Trend

Feb 13, 2026, 4:53 PM EST - 7 weeks ago

Moderna, Inc. (MRNA) Price Forecast: Breakout Signals New Bull Trend

MRNA Starts 2026 Volatile: Examining Rally & Pullback, Outsized Options

Feb 13, 2026, 4:13 PM EST - 7 weeks ago

MRNA Starts 2026 Volatile: Examining Rally & Pullback, Outsized Options

Moderna, Inc. (MRNA) Q4 2025 Earnings Call Transcript

Feb 13, 2026, 12:47 PM EST - 7 weeks ago

Moderna, Inc. (MRNA) Q4 2025 Earnings Call Transcript

Moderna Promises Revenue Growth In 2026, Even As FDA Flu Vaccine Setback Looms

Feb 13, 2026, 10:59 AM EST - 7 weeks ago

Moderna Promises Revenue Growth In 2026, Even As FDA Flu Vaccine Setback Looms

Moderna Narrows Loss, Reiterates 10% Revenue Growth Target

Feb 13, 2026, 7:56 AM EST - 7 weeks ago

Moderna Narrows Loss, Reiterates 10% Revenue Growth Target

Moderna Reports a Narrower-Than-Expected Loss. The Stock Falls After Earnings.

Feb 13, 2026, 7:13 AM EST - 7 weeks ago

Moderna Reports a Narrower-Than-Expected Loss. The Stock Falls After Earnings.

Moderna beats fourth-quarter revenue estimates

Feb 13, 2026, 7:06 AM EST - 7 weeks ago

Moderna beats fourth-quarter revenue estimates

Moderna Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Updates

Feb 13, 2026, 7:00 AM EST - 7 weeks ago

Moderna Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Updates

Moderna Stock Sports Technical Support Ahead Of Earnings

Feb 12, 2026, 3:25 PM EST - 7 weeks ago

Moderna Stock Sports Technical Support Ahead Of Earnings

Why is the FDA refusing Moderna's application for a new mRNA flu vaccine?

Feb 12, 2026, 5:10 AM EST - 7 weeks ago

Why is the FDA refusing Moderna's application for a new mRNA flu vaccine?

The FDA's refusal to review Moderna's application to sell a new flu shot is part of a pattern of regulatory U-turns and overruling of FDA staff by Vinay Prasad, head of the agency's vaccine division

Feb 11, 2026, 9:00 PM EST - 7 weeks ago

The FDA's refusal to review Moderna's application to sell a new flu shot is part of a pattern of regulatory U-turns and overruling of FDA staff by Vinay Prasad, head of the agency's vaccine division

FDA blindsides Moderna with refusal to review flu vaccine application: ‘We're pretty confused'

Feb 11, 2026, 3:15 PM EST - 7 weeks ago

FDA blindsides Moderna with refusal to review flu vaccine application: ‘We're pretty confused'

The FDA Refuses To Review Moderna's Flu Vaccine

Feb 11, 2026, 12:17 PM EST - 7 weeks ago

The FDA Refuses To Review Moderna's Flu Vaccine

Moderna's work developing seasonal vaccines is ‘risky' under current FDA, analyst says

Feb 11, 2026, 10:44 AM EST - 7 weeks ago

Moderna's work developing seasonal vaccines is ‘risky' under current FDA, analyst says

Moderna Stock Sinks. The FDA Delivers a Blow to Its New Flu Vaccine.

Feb 11, 2026, 7:05 AM EST - 7 weeks ago

Moderna Stock Sinks. The FDA Delivers a Blow to Its New Flu Vaccine.

Wall Street Breakfast Podcast: Amazon Adds BETA To Cart

Feb 11, 2026, 6:24 AM EST - 7 weeks ago

Wall Street Breakfast Podcast: Amazon Adds BETA To Cart

AMZN BETA EL WMT

Auto_MA_T_Ka
Auto_MA_T_Ka Apr. 5 at 6:19 PM
Moderna $MRNA is still at its weekly MA support, sitting nicely. -- 📉BEST Respected MA S&R Lines📈
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Apr. 4 at 7:10 PM
$MRNA $RLAY $RXRX $ABSI $SPY
1 · Reply
UsingAGodAlgorithm
UsingAGodAlgorithm Apr. 4 at 3:40 AM
$RH -81% from short entry. We called the top perfectly on this name. One of many calls we were the only ones on all ST to make. Check our profile. $DLTR $SOFI $MRNA $ULTA
0 · Reply
DragonAlgo
DragonAlgo Apr. 3 at 11:44 PM
🐉 $MRNA CALL — DragonAlgo® Signal Contract: MRNA CALL Expiry: 2026-04-10 | Strike: $49.00 | Type: CALL Option Plan (premium): Entry: $2.06 Stop: $1.48 TP1: $2.68 TP2: $3.50 TP3: $4.94 🔗 https://dragonalgo.com
0 · Reply
Davidendz
Davidendz Apr. 3 at 1:37 PM
Biotech gets called “scam” on volatility, but that’s noise. What matters is data and execution. Across names like $BVAXF $BIOV.CSE,$MRNA, $BNTX, and $NVAX, it’s the same cycle: filings, catalysts, then price moves. Clinical progress > headlines.
0 · Reply
DragonAlgo
DragonAlgo Apr. 3 at 8:38 AM
🐉 $MRNA CALL — DragonAlgo® Signal Contract: MRNA CALL Expiry: 2026-04-10 | Strike: $49.00 | Type: CALL Option Plan (premium): Entry: $2.06 Stop: $1.48 TP1: $2.68 TP2: $3.50 TP3: $4.94 🔗 https://dragonalgo.com
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Apr. 2 at 9:26 PM
$MRNA RSI: 39.38, MACD: 0.1618 Vol: 2.11, MA20: 52.31, MA50: 49.09 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
SparkyReturns
SparkyReturns Apr. 2 at 7:15 PM
$ICU I can almost feel the rumble of my new cigarette boat.... And to think my money is helping to bring a life-saving device to market for those most in need in the ICU. Wow. $XERS $ESPR $MRNA $PFE ra
1 · Reply
DragonAlgo
DragonAlgo Apr. 2 at 6:12 PM
🐉 $MRNA PUT — DragonAlgo® Signal Contract: MRNA PUT Expiry: 2026-04-10 | Strike: $47.00 | Type: PUT Option Plan (premium): Entry: $1.16 Stop: $0.83 TP1: $1.50 TP2: $1.96 TP3: $2.77 Active momentum environment. 🔗 https://dragonalgo.com
0 · Reply
G101SPM
G101SPM Apr. 2 at 5:37 PM
#OPTIONACTION $SNAP Apr 5 calls are seeing interest with the underlying stock down 6% (volume: 7.0K, open int: 46.3K, implied vol: ~84%, prev day implied vol: 71%). 2500 contracts traded a single transaction. We noted call activity in the same strike yesterday (see 4/1 13:29 OPTNX). Co is expected to report earnings mid-April. $MSTR Weekly Apr02 137 calls (volume: 15.2K, open int: 16.5K, implied vol: ~75%, prev day implied vol: 69%). Co is expected to report earnings early May. $MRNA Weekly Apr02 53 calls (volume: 16.0K, open int: 16.2K, implied vol: ~76%, prev day implied vol: 72%). 5.9K traded in a single transaction. Co is expected to report earnings in late April. $PYPL Weekly Apr10 45 calls (volume: 5.2K, open int: 650, implied vol: ~45%, prev day implied vol: 42%). 3.9K traded in a single transaction. Co is confirmed to report earnings on May 5 before the open. $AAL Weekly Apr10 10 puts (volume: 5.4K, open int: 5.6K, implied vol: ~62%, prev day implied vol: 57%). Airline shares are falling amid a rise in oil prices. Co is expected to report earnings in late April.
0 · Reply
Lowkeyoptions
Lowkeyoptions Apr. 2 at 5:07 PM
$OMER $RGC $MRNA $DRUG HUGE NEWS ADVANTAGE FOR AMERICAN PHARMA Trump administration prepares up to 100% pharmaceutical tariffs on some imported drugs https://www-cnbc-com.cdn.ampproject.org/v/s/www.cnbc.com/amp/2026/04/02/trump-pharmaceutical-tariffs-100percent.html?amp_js_v=0.1&amp_gsa=1#webview=1&cap=swipe
0 · Reply
IndyOne
IndyOne Apr. 2 at 3:28 PM
$MRNA Massive calls purchased. Have not seen this level of lopsided option statistics.
0 · Reply
IndyOne
IndyOne Apr. 2 at 3:20 PM
$MRNA
0 · Reply
IndyOne
IndyOne Apr. 2 at 2:48 PM
$MRNA BULL FLAG !!!
0 · Reply
erevnon
erevnon Apr. 2 at 2:37 PM
Barclays maintains Moderna $MRNA at Equal-Weight and raises the price target from $25 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
DragonAlgo
DragonAlgo Apr. 2 at 12:46 AM
🐉 $MRNA CALL — DragonAlgo® Signal Contract: MRNA CALL Expiry: 2026-04-10 | Strike: $51.00 | Type: CALL Option Plan (premium): Entry: $1.79 Stop: $1.29 TP1: $2.33 TP2: $3.05 TP3: $4.31 Momentum tape remains active. 🔗 https://dragonalgo.com
0 · Reply
Lion0fWallSt
Lion0fWallSt Apr. 1 at 11:17 PM
$CAPR $MRNA $SLS $SRPT $PFE https://youtu.be/LI5d5s7dG_c
1 · Reply
KingZack25
KingZack25 Apr. 1 at 9:14 PM
$MRNA curious to see if they rollover their calls into next week again. They rolled over last week into this week. Once they finish crushing these calls we should pump again. Hopefully they dont roll them over
0 · Reply
taxplanr
taxplanr Apr. 1 at 8:36 PM
What do you make of this testimony in front of the German Bundestag? $PFE $BNTX $MRNA https://www.instagram.com/reel/DWmYyx1jm4u/?igsh=MTBud3hycjBvM2J4ZA==
0 · Reply
cbroth1
cbroth1 Apr. 1 at 6:40 PM
$MRNA relentless stop loss raids followed by short covering on weakness
0 · Reply
IndyOne
IndyOne Apr. 1 at 5:06 PM
$MRNA Moderna becomes the only scaled mRNA player with a clear regulatory path with Pfizer and BioNtech exit. Moderna's combo is the strategic advantage that already succeeded in Phase 3. Pfizer/BioNTech failed at a COVID‑only trial and with combo strategy. BioNtech seems rudderless. Moderna executes and BioNtech does not. Moderna is advancing a COVID + flu combo (mRNA‑1083 / mCOMBRIAX) with: *Positive Phase 3 data *EMA positive opinion already *Submission of Phase 3 results to FDA Check and mate. One million dollar BULL FLAG.
0 · Reply